November 17, 2024, New York, NY — Cayuga Biotech, a company that develops drugs that harness the body’s innate ability to stop bleeding, today presented preclinical data on its first generation, first-in-class, polyphosphate (polyP)-based therapy designed to address life threatening hemorrhage. The results demonstrated that the polyP-SNP complex can overcome hemodilute, acidotic and hypothermic conditions, which contribute to poor survival. Cayuga was awarded best oral presentation for Plasma, Hemostasis and Transfusion Medicine at the 19th International Symposium on Blood Substitutes (ISBS).
“There is great unmet need for interventions that accelerate hemostatic control at noncompressible bleeding sites under conditions known as “the lethal triad,” said Damien Kudela, PhD, Chief Science Officer of Cayuga Biotech and inventor of the polyP-SNP complex. “We demonstrated the ability to restore clotting even under severe conditions that led to failure for control.”
The polyP-SNP complex is an investigational, first-in-class, polyP-based therapy. As an injected drug that is inert in healthy tissue, the polyP-SNP complex travels via the bloodstream to any site of bleeding and acts to accelerate the clotting response with low potential for causing clotting in healthy tissue, a problem that has limited development for other injectable drugs to treat hemorrhage
“A synthetic short-chain polyphosphate (polyP) complexed with silica nanoparticle (SNP, polyP SNP), corrects coagulopathy under hemodilute, hypothermic, or acidotic conditions as assessed by in vitro coagulation assays” (Oral Abstract #66)
About Hemorrhage
Nearly 2 million people globally per year die of hemorrhage, the majority of which is preventable. The top causes of preventable death by hemorrhage are non-compressible hemorrhage sites (such as internal bleeding and penetrating injury) and delays in hemostatic control, neither of which are adequately addressed by today’s current care model. Due to the nature of non-compressible hemorrhage sites, the complexity of clinical intervention is time consuming and delays in treatment often lead to patient death.
About Cayuga Biotech, Inc.
Cayuga is developing novel biomimetic therapies leveraging inorganic polyphosphate, a polymer that modulates the healing response. The company has an optimized polyP-SNP complex in late preclinical development for the treatment of acute major hemorrhage, a discovery-stage novel composition for the treatment of inherited bleeding disorders, as well as a portfolio of early-stage programs focused across the healing continuum. To learn more, please visit www.CayugaBiotech.com.
Contact:
Andrea Ashford-Hicks
Media@cayugabiotech.com